Cervical dysplasia is typicallyassociated with human papillomavirus (HPV) infection, smoking, and is morecommon in women above age 30. However, cervical dysplasia is a preventable andcervical screening tests are useful to diagnosis precancerous stage.
Statistics:
The global CervicalDysplasia Market is estimated to account for US$ 447.7 Mn in terms of valueby the end of 2019.
Global Cervical Dysplasia Market:Drivers
Increasing investment in cervicaldysplasia is expected to propel growth of the global cervical dysplasia marketover the forecast period. For instance, in June 2020, Cel-Sci, a phase 3 cancerimmunotherapy company, raised approximately US$ 10 million through the exerciseof warrants.
Global Cervical Dysplasia Market:Opportunities
Leveraging virtual space isexpected to offer lucrative growth opportunities for players in the globalcervical dysplasia market. Diagnosing cervical dysplasia in first world countriessuch as the U.S. has minimized the death rate of cervical cancer. However,logistics behind this diagnosis process is difficult to implement in developingcountries due to women from remote villages rarely return to the clinic forfollow-ups. Smartphone application is developed to provide a point-of-carepreliminary diagnosis. Ultimately, the application would screen samplesobtained and immediately provide a preliminary diagnosis
* The sample copy includes: Report Summary, Table of Contents,Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1486
Global Cervical Dysplasia Market:Restraints
Low awareness of cervicaldysplasia in emerging economies is expected to hinder growth of the globalcervical dysplasia market. Majority of women in emerging economies still do nothave a clear understanding about cervical cancer screening tests and its earlydetection. Additionally, in low-resource settings, effective screeningawareness programs have been difficult to implement, thereby increasing the cervicalcancer mortality rates.
Key Takeaways:
The global cervical dysplasiamarket was valued at US$ 447.7 Mn in 2019 and is forecast to reach a value ofUS$ 784.8 by 2027 at a CAGR of 7.3% between 2020 and 2027. Increasingprevalence of cervical cancer is expected to drive the market growth during theforecast period.
Diagnostic Test segment helddominant position in the global cervical dysplasia market in 2019, accountingfor 86.8% share in terms of value, increasing technological advancement alongwith product approvals is expected to assist the segment growth.
Market Trends
Adoption of AI for predictivecancer is expected to propel growth of the global cervical dysplasia marketover the forecast period. For instance, in September 2020, Google Cloudreceived a contract to supply Veterans Affairs hospitals and Defense HealthAgency treatment facilities with AI for predictive cancer and diseasediagnosis.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/cervical-dysplasia-diagnostic-market-1486
Moreover, development of advanceddiagnostic tools is also expected to aid in growth of the global cervicaldysplasia market. For instance, in June 2020, researchers from the Institute ofAdvanced Study in Science and Technology, India, reported development of arobust fully automated software-based solution using Pap smear images to detectabnormal growth or development of tissues in the cervix — the lower part of theuterus that connects to the vagina.
Global Cervical Dysplasia Market:Competitive Landscape
Major players operating in theglobal cervical dysplasia market include, F. Hoffmann La-Roche Ltd., QIAGENN.V., Becton, Dickinson and Company, OncoHealth Corporation, Quest Diagnostics,Inc., Hologic, Inc., Abbott Laboratories, ASKA Pharmaceutical Co., Ltd.,Asieris Pharmaceuticals, BetterLife Pharma Inc., and KinoPharma, Inc.
Global Cervical Dysplasia Market:Key Developments
Major players in the globalcervical dysplasia market are focused on approval and launch of new products toexpand their product portfolio. For instance, in July 2020, AsierisPharmaceuticals, a China-based biotech company, received Clinical Trial Approval(CTA) from China's National Medical Products Administration (NMPA) for theglobal, multi-centered Phase III clinical trial of its photodynamic drug-devicecombination product, APL-1702 (Cevira), which is being developed for thenon-surgical treatment of high-grade cervical dysplasia.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1486
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
